Nordroden/iStock via Getty Images I highlighted IDEX’s (NYSE:IEX) weak growth in Health & Science Technologies segment in my previous coverage published in February 2024. The company released its Q1 FY24 result on April 23rd and reaffirmed its full-year guidance. While I acknowledge that the Health & Science Technologies will continue to face challenges in FY24, IDEX’s order growth has already started to moderate. I reiterate 'Buy' rating with a fair price target of $220 per share. Order Moderation In Q1 FY ...